Sugi Predict

Sugi Predict / Targets / FOXM1

FOXM1

Forkhead box protein M1 · Q08050 · FOXM1 on Sugi Atlas →

3,746 patent compounds predicted against FOXM1, 2,289 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4546781 SCHEMBL4546781 0.35 4/20
SCHEMBL4546786 SCHEMBL4546786 0.35 4/20
SCHEMBL432256 SCHEMBL432256 0.79 3/20
SCHEMBL417495 SCHEMBL417495 0.38 3/20
SCHEMBL923466 SCHEMBL923466 0.38 3/20
SCHEMBL3037609 SCHEMBL3037609 0.38 3/20
SCHEMBL3040478 SCHEMBL3040478 0.38 3/20
SCHEMBL3043744 SCHEMBL3043744 0.38 3/20
Pentolinium Pentolinium (SCHEMBL210048) 0.36 3/20
SCHEMBL2158184 SCHEMBL2158184 0.36 3/20
SCHEMBL2393255 SCHEMBL2393255 0.36 3/20
SCHEMBL3674134 SCHEMBL3674134 0.36 3/20
Bromide Bromide (SCHEMBL250430) 0.36 3/20
SCHEMBL4546788 SCHEMBL4546788 0.35 3/20
SCHEMBL2930520 SCHEMBL2930520 0.34 3/20
SCHEMBL812356 SCHEMBL812356 0.34 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL5567515) 0.34 3/20
SCHEMBL3812862 SCHEMBL3812862 0.33 3/20
SCHEMBL2400137 SCHEMBL2400137 0.33 3/20
SCHEMBL429729 SCHEMBL429729 0.85 2/20

Clinical trials — most relevant to FOXM1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer PHASE3COMPLETED
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery PHASE3COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors PHASE2RECRUITING
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium PHASE2COMPLETED
Cocoa Flavanols for Modulating Immune Response and Accelerating Recovery PHASE1/PHASE2COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome PHASE1NOT_YET_RECRUITING
FoxO3a and PU.1 in Acute Lymphoblastic Leukemia nanUNKNOWN
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis nanUNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome nanCOMPLETED
MIF Involvement in AML nanACTIVE_NOT_RECRUITING
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck nanRECRUITING
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction nanCOMPLETED
Characterization of Ovarian Cancer Stem Cell nanUNKNOWN
Immune Cell Response to Stimuli nanRECRUITING
Expression of Longevity Genes in Response to Extended Fasting nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Optimized Remission in Alcohol-related Liver Cirrhosis nanRECRUITING
Vascular Senescence and Atherosclerotic Plaque Vulnerability nanRECRUITING
Hepatic Energy Fluxes in NASH and NAS Patients nanACTIVE_NOT_RECRUITING
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis nanACTIVE_NOT_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
The Activation of Hippo Pathway in Nasal Polyps nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FOXM1 binder may also engage these)

ProteinNameSimilarity
O08696 — 1.000 O08696 →
P97691 — 0.999 P97691 →
P10244 — 0.999 P10244 →
Q5W1J6 — 0.998 Q5W1J6 →
TET3 Methylcytosine dioxygenase TET3 0.998 landscape →
Q8BZ32 — 0.996 Q8BZ32 →
Q499D0 — 0.996 Q499D0 →
KDM3B Lysine-specific demethylase 3B 0.995 landscape →
Q8R5I7 — 0.995 Q8R5I7 →
P56931 — 0.995 P56931 →
Q3V0A6 — 0.995 Q3V0A6 →
Q32NH9 — 0.995 Q32NH9 →
Q80WT2 — 0.995 Q80WT2 →
Q9H869 — 0.995 Q9H869 →
Q90655 — 0.994 Q90655 →
Q949U2 — 0.994 Q949U2 →
Q8BG36 — 0.994 Q8BG36 →
Q9EPW2 — 0.994 Q9EPW2 →
Q63449 — 0.994 Q63449 →
Q2KHR2 — 0.994 Q2KHR2 →
F1QDF8 — 0.994 F1QDF8 →
Q9ET54 — 0.994 Q9ET54 →
Q9I9H2 — 0.994 Q9I9H2 →
Q5VV67 — 0.994 Q5VV67 →
Q03172 — 0.994 Q03172 →
Q76I79 — 0.994 Q76I79 →
Q14209 — 0.994 Q14209 →
Q6P1W5 — 0.994 Q6P1W5 →
Q6NZN1 — 0.993 Q6NZN1 →
A6X8Z5 — 0.993 A6X8Z5 →